Preeclampsia (PE) is a gestational hypertensive syndrome affecting between 5 and 8% of all pregnancies. Although PE is the leading cause of fetal and maternal morbidity and mortality, its molecular etiology is still unclear. Here, we show that ELABELA (ELA), an endogenous ligand of the apelin receptor (APLNR, or APJ), is a circulating hormone secreted by the placenta. Elabela but not Apelin knockout pregnant mice exhibit PE-like symptoms, including proteinuria and elevated blood pressure due to defective placental angiogenesis. In mice, infusion of exogenous ELA normalizes hypertension, proteinuria, and birth weight. ELA, which is abundant in human placentas, increases the invasiveness of trophoblast-like cells, suggesting that it enhances placental development to prevent PE. The ELA-APLNR signaling axis may offer a new paradigm for the treatment of common pregnancy-related complications, including PE.
T he placenta is a mammalian-specific organ and a critical source of factors responsible for remodeling the maternal cardiovascular system to accommodate the needs of the growing fetus. Defects in placentation often result in intrauterine growth restriction (IUGR) for the fetus and gestational complications such as preeclampsia (PE) for the mother. PE affects 5 to 8% of all pregnancies and remains the leading cause of fetal and maternal morbidity and mortality. Current challenges in PE include early detection and the availability of effective drugs that do not adversely affect fetal development. ELABELA encodes an endogenous ligand for the apelin receptor (APLNR, or APJ). It is first detected in preimplantation human blastocysts and controls the self-renewal of embryonic stem cells (1) . In the adult, its expression is restricted to a few tissues, including two endocrine organs, the kidneys and the placenta (1) . In rodents, the onset of Ela expression coincides with zygotic transcription ( fig. S1A ), peaks at the blastocyst stage, and is similarly restricted in the adult. In lower vertebrates, Ela is required for proper endoderm development, and Ela-deficient zebrafish have profound cardiac malformations resulting from impaired migration of cardiac progenitors (2, 3) . Zebrafish lacking both Ela and Apelin (Apln), the alternate ligand for Aplnr, have defects in vasculogenesis owing to impaired migration of angioblasts to the midline (4) . At present, the molecular effects of ELA signaling downstream of APLNR are unknown, and its involvement in mammalian development and physiology has not been addressed.
To delineate the contribution of ELA to mammalian development, we generated Ela knockout (Ela D/D ) mice using homologous recombination to delete exon 3 encoding the mature ELA peptide ( Fig. 1, A and B, and fig. S1 , B and C). This strategy did not result in nonsense-mediated decay of the Ela D mRNA (Fig. 1C ) and presumably preserves the potential noncoding functions of the Ela transcript (5) . Only half of the expected Ela D/D mice from heterozygous intercrosses were obtained at weaning (Fig. 1D) (Fig. 1D ). This apparent maternal contribution is not due to Ela mRNA being deposited in the oocyte, because the onset of Ela transcription is strictly zygotic (fig. S1A ). Rather, we surmise that ELA might be provided by the maternal circulation or uterine environment. At embryonic day 10.5 (E10.5), Ela D/D embryos can be grouped into three classes: 48.9% were phenotypically normal (class 1), 8.5% were delayed with a hypovascular yolk sac (class 2), and 42.6% had avascular yolk sacs and severe embryonic vascular malformations (class 3) ( fig. S1D ) that are similar to those previously reported for Apj knockouts (Fig. 1, E to J) . In affected Ela D/D embryos, vasculogenesis appears to be initiated, as evidenced by the presence of a CD31/Pecam + endothelial plexus, which subsequently fails to undergo remodeling and angiogenic sprouting to form organized vitelline vessels, dorsal aorta, outflow tract, and intersomitic vessels (Fig. 1, K to S, and fig. S1 , E to J). The heart tube is poorly looped, with reduced smooth actin muscle (SMA) staining (Fig. 1 , Q to S), and the most severely affected embryos (class 3) have pericardial edema (fig. S1, K and L). These cardiac defects are consistent with the first postgastrulation expression of Ela in the primitive foregut overlying the developing heart tube ( Fig. 1, T and U) (6) . Surprisingly, Ela is not detected in endothelial precursors of the yolk sac (Fig. 1W) , whereas Apj expression is ubiquitous in embryonic, allantoic, and yolk sac mesoderm, which gives rise to endothelial cells (Fig. 1, V and X). The expression patterns of Ela and Apj suggest that the observed cardiac defects are partly due to insufficient blood flow to stimulate angiogenesis. Outside of the developing heart tube, Ela is first detected in the chorionic trophoblast of the developing placenta ( Fig. 1U and  fig. S1 , M and N) and is robustly up-regulated after allantoic fusion ( Fig. 2A) , becoming restricted to syncytiotrophoblasts (STs) at E10.5 ( Fig. 2, C (Fig. 2 , B, D, and D′). Hence, ELA may signal to APJexpressing cells in a paracrine manner but may also be circulating systemically because the chorioallantoic placenta is perfused by maternal and fetal blood. Indeed, endogenous ELA is detected by enzyme-linked immunosorbent assay (ELISA) in the serum of pregnant females, peaking at midgestation, but not in nonpregnant mice (Fig.  2G) . Systemic ELA in a pregnant mother is contributed both maternally and embryonically (Fig.  2H) , the former reflecting secretion from the maternal endometrial stroma and kidneys ( fig.  S2 , A to C) and the latter from embryonically derived STs (Fig. 2C) . We therefore conclude that ELA is a pregnancy-associated hormone secreted by the developing conceptus and placenta. Ela D/D placentas from affected embryos have thin labyrinths (Fig. 2, I placentas from unaffected (class 1) or mildly affected (class 2) embryos, which are intermediately vascularized, nonetheless exhibit delayed ST differentiation, as indicated by reduced alkaline phosphatase and syncytin-1 staining at E10.5 (Fig. 2, M and N, and fig. S2 , J and K). Although such placentas eventually develop, allowing embryo survival, the labyrinth of mutant versus WT placentas remains thinner until the end of gestation ( fig. S2E) .
To understand the pathogenesis of Ela deficiency causing placental dysfunction, we isolated placentas denuded of maternal decidua from WT and Ela D/D conceptuses (Fig. 3A) . We chose to carry out the analysis by E9.5 to avoid the confounding transcriptional changes brought about by major cardiovascular anomalies seen at E10.5. Ela D/D placentas were categorized into class 1 or class 3 based on the gross morphology of the corresponding embryos ( fig. S3A ). RNA sequencing (RNA-seq) and principal components analysis revealed that both class 1 and 3 Ela Concurrently, and possibly as part of the elevated hypoxic response, Ela deficiency results in an up-regulation of pro-angiogenic genes, even in class 1 placentas that are bereft of discernible vascular defects (Fig. 3C) .
A close examination of differentially regulated genes revealed a dramatic enrichment in genes and pathways defining endothelial tip cells (Fig. 3 , D and E) (9) . Tip cells form the leading edge of sprouting endothelial cells and migrate in response to pro-angiogenic signals (10) . Functioning in the same way as axonal growth cones, tip cells extend filopodia to determine the direction of the angiogenic sprout, whereas trailing stalk cells proliferate to enable lumenogenesis and extension of the vascular sprout (11, 12) . Gene ontology analysis confirmed functional hallmarks of tip cell identity such as vascular endothelial growth factor (VEGF) and semaphorin signaling, hormone secretion, axonogenesis, and filopodia extension (Fig. 3D ). Quantitative polymerase chain reaction (qPCR) analysis validated the 2 of 7 up-regulation of tip cell markers and angiogenic genes, including Vegfa, Apln, Plgf, Esm1, Igfbp3, Flt4, and Adm (Fig. 3F ). This was confirmed by direct immunostaining against endogenous Esm1, a specific tip cell marker (9, 13, 14) , which was significantly up-regulated in both number and intensity in Ela D/D placental sections, indicating ectopic tip cell differentiation (Fig. 3, G to I). Using a Apln-LacZ knockin reporter (15) ELA also enters the maternal circulation, where it acts systemically to prevent symptoms of preeclampsia during pregnancy. Tb, trophoblast. Data are depicted as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 of two-sample Student's t test, unless otherwise stated.
the expression of tip cell genes such as Esm1 and Apln. Defects in genes required for placental development and angiogenesis frequently lead to preeclampsia in mice (18, 19) . In light of the placental defects seen in Ela D/D conceptuses, including a prominent gene signature of increased inflammatory response ( fig. S4A) , and increased expression of Esm1 (20, 21) and Adm (22) , which have been linked to PE in humans, we hypothesized that Ela D/D mothers might exhibit symptoms of PE. We thus assessed Ela D/D pregnant mice for signs of proteinuria and hypertension, two diagnostic hallmarks of PE. Indeed, by decreasing the number of WT Ela alleles in fetuses and their pregnant mothers, the urine protein/creatinine ratio at gestational day (GD) 15 increased dramatically, indicating an inverse correlation between endogenous ELA levels and the severity of proteinuria (Fig. 4A) . At the end of pregnancy, histology and transmission electron microscopy of kidney glomerular sections revealed signs of endotheliosis in Ela D/D pregnant mothers ( fig. S4 , B to G), a unique renal pathology of women suffering from PE (23, 24) .
Glomeruli from Ela
D/D pregnant mothers were swollen and had occluded capillaries, with evidence of protein and vesicular deposition on endothelial cells, absence of proper endothelial fenestration, and coagulation of red blood cells in capillary lumens ( fig. S4, B to G) . Podocytes, on the other hand, appeared normal. Proteinuria was not observed in nonpregnant Ela D/D mice ( fig. S4H ), indicating that the renal pathology is unique to pregnancy. Next, we employed a tailcuff method to measure systolic blood pressure (BP) throughout pregnancy, after training the mice for a minimum of 3 days before mating. Although there were no significant differences in the nonpregnant baseline BP between WT and Ela D/D mice, pregnant Ela D/D mothers (mated to Ela D/D fathers) had significantly higher systolic BP, which returned to normal levels postparturition (Fig. 4B) , and delta BP (pregnant BP minus baseline BP) on GD 16 and 18 (Fig. 4C) . In addition, Ela D/D pups from Ela D/D mothers collected by caesarean section at E18.5 were significantly lower in weight compared with WT pups from WT mothers (Fig. 4D) . This is reminiscent of IUGR, which frequently accompanies PE and placental insufficiency. Our findings indicate that Ela D/D mice suffer from PE and suggest that ELA is necessary for regulating maternal cardiovascular homeostasis to prevent gestational hypertension. To determine whether the loss of ELA is upstream of well-established biomarkers of human PE, we measured both maternal plasma and placental mRNA levels of sFlt1 (24) , Vegf (25) , and Plgf (19, 26) . At late gestation, Ela D/D placentas have increased levels of sFlt1, Vegfa, and Plgf mRNA ( fig. S4I ), although these transcriptional changes did not translate into significantly elevated plasma levels of the respective proteins ( fig. S4 , J to L). Altogether, these data indicate that Ela D/D mice are not developing PE symptoms simply due to a decrease in the Plgf/sFlt1 ratio but suggest that ELA acts independently of, and possibly earlier than, these angiogenic factors in the pathogenesis of PE.
It is noteworthy that overexpression of Apln (Fig. 3F) fig. S5C ). To further investigate the biological differences between APLN and ELA, we treated APJ-expressing primary allantoic cultures from somite stage embryos with equal concentrations of ELA, APLN, or both ( fig. S5D ). We found that ELA and APLN elicited opposite effects on the expression of Esm1 and several hypoxic response genes ( fig. S5, D to E′) . Lastly, we found that ELA could directly repress the expression of Apln in these allantoic explants ( fig. S5F ), raising the possibility that Apln derepression in the absence of ELA drives excessive and pathogenic tip cell differentiation. Indeed, we find that in a litter of Ela D/D null embryos, the most severely affected embryos are the ones expressing the highest levels of Apln ( fig. S5G) . Moreover, the two ligands display distinct spatiotemporal expression where Ela is highly concentrated and restricted to the developing heart, caudal neural tube and trophoblasts, whereas Apln is diffusely expressed and widespread in all embryonic and extraembryonic tissues ( fig. S5, H to I′) . Altogether, our data demonstrate that Ela and Apln are biologically distinct and elicit opposing effects on placental angiogenesis and symptoms of PE.
Because ELA appears to act as a systemic hormone during pregnancy, we asked whether administration of synthetic ELA during pregnancy may alleviate PE symptoms. ELA infusion did not affect BP and proteinuria parameters in pregnant WT mice (Fig. 4F) , nor did it have noticeable side effects on embryogenesis, as measured by fetal weight, morphology, and subsequent postnatal development. We were able to normalize proteinuria (Fig. 4E) and BP (Fig. 4F) in Ela D/D pregnant mothers infused with recombinant ELA from GD 7.5 onwards, which is consistent with our model that ELA acts as a systemic hormone. Furthermore, infusion of ELA rescued the weight of Ela D/D fetuses ( Fig. 4D ) and glomerular endotheliosis in pregnant Ela D/D mothers, as assayed by periodic acid-Schiff and a-fibrinogen staining ( fig. S6 ).
In humans, we find that ELA is predominantly expressed in villous cytotrophoblasts and STs of first-trimester placental tissue (8 + 3 weeks) (Fig.  4G) and term placentas (fig. S4, M and N) . In PE, extravillous trophoblast invasion and subsequent spiral artery remodeling are frequently incomplete, leading to shallow and defective placentation (27) . We therefore hypothesized that, in humans, ELA might contribute to trophoblast invasion. Indeed, addition of ELA to trophoblast-like JAR choriocarcinoma cells significantly increased their invasiveness in transwell invasion assays (Fig. 4H ) (28) . These data suggest that ELA, secreted from the ST layer, has a paracrine effect on trophoblasts differentiating into invasive extravillous trophoblasts. ELA activity potentiates invasion and might enhance subsequent spiral artery remodeling to prevent the development of PE during human pregnancy.
Pregnancy is a unique physiological state associated with increased cardiovascular demand and burden. Many processes work in concert to impart cardiovascular homeostasis in the pregnant female, although to date these are largely unknown. In the mouse, we propose that ELA produced by placental trophoblasts functions in two ways to prevent gestational hypertension (Fig. 4I) . First, ELA exerts paracrine effects on fetal endothelial cells, where it curbs inappropriate differentiation of endothelial tip cells. This enables normal branching angiogenesis and the formation of an adequate labyrinth network required for proper perfusion. Second, ELA enters the maternal circulation to regulate cardiorenal function. We speculate that the latter role might have a direct effect on the maternal endothelium (e.g., through the stimulation of vasodilatory mechanisms such as nitric oxide production) (29) or by regulating diuresis (30) . Although the PE-protective effects are presumably achieved through APJ signaling in endothelial cells, we do not rule out a possible contribution from as-yet-unidentified ELA receptors (1) . ELA deficiency in the mouse leads to classical PE symptoms together with gross abnormalities in placental development. Similarly, ELA is expressed by trophoblasts in the chorionic villi of human placentas and potentiates trophoblast invasion in vitro. We speculate that in humans ELA might contribute to placentation by stimulating trophoblast migration and invasion, in addition to direct effects on the maternal endothelium, although these remain to be investigated.
In conclusion, we propose that ELA is a circulating hormone produced by the mammalian placenta to ensure cardiovascular integrity of both mother and fetus during pregnancy. Our results raise the possibility that transient enforcement of the ELABELA-nergic axis might therefore be beneficial for conditions that display hypertension, such as, but not limited to, preeclampsia.
